IMGN News and Press, ImmunoGen Inc. From 05/03/23

2023-05-03 08:46:05 ET Overall, the stock market is facing a serious case of the jitters on Wednesday morning, as investors wait anxiously for the coming decision on interest rates from the Federal Reserve later this afternoon. Stock index futures are pointing toward a slightly higher open ...

2023-05-03 08:07:32 ET ImmunoGen ( NASDAQ: IMGN ) said its ovarian cancer drug Elahere showed statistically significant improvements in progression-free survival (PFS) and overall survival (OS) in a confirmatory phase 3 trial trial. Based on these data, the company pla...

Results Show Statistically Significant Improvements in PFS, ORR, and OS Compared to Chemotherapy First Medicine to Demonstrate an Overall Survival Advantage in Platinum-Resistant Ovarian Cancer Submission of MAA in Europe and sBLA in US Anticipated in H2 2023 Conference Ca...

2023-04-28 13:20:06 ET ImmunoGen, Inc. (IMGN) Q1 2023 Earnings Conference Call April 28, 2023 08:00 AM ET Company Participants Anabel Chan - Head, Investor Relations Mark Enyedy - President & Chief Executive Officer Anna Berkenblit - Chief Medical Officer ...

2023-04-28 12:03:12 ET Shares of ImmunoGen (NASDAQ: IMGN) rose by almost 27% Friday morning after the company announced its first-quarter results. The biotech company's stock had previously been having a sluggish 2023 -- it's now up by 9.7% year to date. The company, whi...

2023-04-28 11:12:16 ET ImmunoGen ( NASDAQ: IMGN ) has seen a ~22% increase in trading after exceeding profit and revenue estimates for the first quarter, driven by strong net sales of its ovarian cancer treatment, Elahere, as well as the recognition of a $15M upfront fee recei...

2023-04-28 10:03:38 ET Gainers: Tempest Therapeutics ( TPST ) +72% . CVRx ( CVRX ) +25% . ImmunoGen ( IMGN ) +22% . Apyx Medical ( APYX ) +17% . bluebird bio ( BLUE ) +17% . Losers: Hillstream BioPharma ( HILS ) -56%...

2023-04-28 06:36:57 ET ImmunoGen press release ( NASDAQ: IMGN ): Q1 GAAP EPS of -$0.16 beats by $0.09 . Revenue of $49.87M (+31.0% Y/Y). For further details see: ImmunoGen GAAP EPS of -$0.16 beats by $0.09, revenue of $49.87M

Strong Adoption of ELAHERE; Net Sales of $29.5 Million in First Full Quarter of Launch Top-Line Results from Confirmatory MIRASOL Trial Anticipated in Early May; Expected to Support Full Approval of ELAHERE in the US and Expansion into Europe Announced Non-Dilutive Financing for U...

2023-04-27 15:09:37 ET The stock market’s current volatility may have piqued your interest in investing in penny stocks . Usually priced below $5, these stocks are known for their significant price fluctuations and potential for high returns, albeit with considerable risks. In th...